Health News

FDA Approves New Leukemia Rx
On January 19, 2016, the U.S. Food and Drug Administration approved ofatumumab (Arzerra Injection, Novartis Pharmaceuticals Corporation) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL).
A New Treatment Option for Adult Leukemia
Patients may now have an alternative to chemotherapy as their first line of defense against chronic lymphocytic leukemia (CLL).
An Antibiotic Benefit for Childhood Leukemia
For kids with acute lymphoblastic leukemia (ALL), bacterial infections can cause dangerous complications. But a new treatment option may be able to help.
Bendeka Gets the Green Light
JERUSALEM & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announce that the U.S. Food and Drug Administration (FDA) has approved BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine.
A Big Month for Multiple Myeloma
Before November, there were seven FDA-approved medications to treat multiple myeloma. Now that November is over, there are 10.
A New Multiple Myeloma Treatment
Another treatment for multiple myeloma just got an OK from the FDA.
FDA Approves New Multiple Myeloma Rx
Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.
New Multiple Myeloma Rx Gets Go-Ahead
A new FDA approval could give another option to multiple myeloma patients who haven't had luck with past treatments. {C}
Ninlaro Approved for Multiple Myeloma
Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.
New Rx for Multiple Myeloma
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments.